Metagenomi

0 reviews

Metagenomi Therapeutics is an in vivo genome editing company dedicated to developing curative genetic medicines. Founded on the science of metagenomics—the study of genetic materials recovered from natural environments—Metagenomi has discovered and developed a suite of novel editing tools capable of correcting various genetic mutations across the human genome. The company focuses on high-value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Key Features and Functionality: - Proprietary Genome Editing Toolbox: Metagenomi's platform includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and CRISPR-associated transposases (CAST). This diverse and modular toolbox enables precise targeting and correction of genetic mutations. - Metagenomics-Powered Discovery Platform: By analyzing genetic material from natural environments, Metagenomi has built an extensive library of novel gene editing systems. This approach has led to the identification of over 20,000 specific editing systems, expanding the possibilities for therapeutic applications. - AI-Enabled Screening and Modular Engineering: The company employs artificial intelligence and machine learning to screen its metagenomics database, identifying high-performing CRISPR nucleases and other effector enzymes. This process allows for rapid development and optimization of gene editing systems tailored to specific therapeutic needs. Primary Value and Solutions: Metagenomi's innovative approach addresses the limitations of existing gene editing technologies by providing a comprehensive suite of tools capable of correcting a wide range of genetic mutations. This capability opens new avenues for treating genetic disorders, offering the potential for curative therapies where current options are limited or nonexistent. By leveraging its proprietary technologies, Metagenomi aims to revolutionize gene editing for the benefit of patients worldwide.